. 2015 Apr 10;172(12):3141–3150. doi: 10.1111/bph.13116

Table 3.

Effect of RTKIs on VEGF₁₆₅a concentration–response parameters

Vandetanib			Pazopanib			Cediranib			Sorafenib
nM	pEC₅₀	% E_max	nM	pEC₅₀	% E_max	nM	pEC₅₀	% E_max	nM	pEC₅₀	% E_max
0	9.90 ± 0.14	100.0	0	9.66 ± 0.11	100.0	0	9.68 ± 0.09	100.0	0	9.72 ± 0.06	100.0
30	9.77 ± 0.10	81.0 ± 4.1	1	9.50 ± 0.09	85.2 ± 7.0	0.3	9.40 ± 0.10	64.8 ± 10.4^*	3	9.50 ± 0.05	70.1 ± 6.9^*
100	9.75 ± 0.12	58.5 ± 5.7^*	3	9.43 ± 0.13	71.4 ± 5.2^*	1	9.28 ± 0.12	31.1 ± 6.6^*	10	9.33 ± 0.06^*	52.9 ± 5.1^*
300	9.41 ± 0.14^*	29.5 ± 7.9^*	10	9.14 ± 0.16^*	32.8 ± 2.0^*	3	9.13 ± 0.18^*	8.8 ± 1.9^*	30	9.00 ± 0.13^*	18.9 ± 8.9^*

pEC₅₀ and E_max values for VEGF₁₆₅a obtained in the presence of increasing concentrations of four RTKIs.

P < 0.05 compared with corresponding control in the absence of RTKI (one-way anova). Values are mean ± SEM from six (cediranib), five (pazopanib), seven (sorafenib) and five (vandetanib) separate experiments.